Backed by Science

OvaStem® is a patented stem cell based treatment for treatment of premature ovarian insufficiency/failure. It is provided by Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company committed to improving patient lives in the areas of urology, orthopedics, and gynecology utilizing stem cells derived from autologous bone marrow. OvaStem® is the direct result of research and collaboration between some of the preeminent scientists and physicians in the world who specialize in gynecology, obstetrics, reproductive endocrinology, and stem cell therapy.

Developed by Leaders

OvaStem® is a cutting edge technology currently being developed by leaders in the field of regenerative medicine, reproductive endocrinology, and gynecology as a treatment option for premature ovarian insufficiency of failure. The procedure offers the possibility of pregnancy without the requirement of a donor egg.

Proposed Mechanisms of Action for Bone Marrow Aspirate in Premature Ovarian Failure

Polonio, A. M., García-Velasco, J. A., & Herraiz, S. (2020). Stem Cell Paracrine Signaling for Treatment of Premature Ovarian Insufficiency.

Front Endocrinol (Lausanne), 11, 626322. https://doi.org/10.3389/fendo.2020.626322 

For More Information

Contact Us